Changes in weight secondary to improved odor perception in chronic rhinosinusitis with nasal polyps' patients treated with Dupilumab.
BMI
Biologics
Chronic rhinosinusitis with nasal polyps
Dupilumab
Hyposmia
Olfaction
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
received:
12
06
2024
accepted:
30
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
aheadofprint
Résumé
The advent of biologic therapies, notably Dupilumab, has transformed therapeutic approaches to nasal polyposis. This retrospective multicentric study aimed to investigate weight changes in CRSwNP patients undergoing Dupilumab treatment and explore potential correlations with olfactory improvement. Ninety-six patients with CRSwNP were followed for at least 12 months, with assessments including BMI (Body Mass Index), olfactory function, and disease severity. Significant increases in BMI and olfactory perception were observed after 1 year of Dupilumab treatment (p < .001). Subgroup analysis showed that patients with hyposmia and normosmia at T12 (1-year follow up) experienced significant weight gain (p < .001) alongside improved olfaction (both p < .001). Conversely, patients with anosmia after 1 year of therapy and also patients with stable or worsened olfaction did not show significant BMI changes (respectively p = .201 and p = .107). While these findings suggest a correlation between olfactory improvement and weight gain/BMI, factors like improved nasal airflow and corticosteroid cessation under Dupilumab treatment may also influence weight in CRPwNP patients. The study highlights the need for further research to elucidate the causal relationship and long-term implications of Dupilumab-induced olfactory improvement on weight regulation.
Identifiants
pubmed: 39404880
doi: 10.1007/s00405-024-09021-0
pii: 10.1007/s00405-024-09021-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Bachert C, Han JK, Wagenmann M et al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol 147(1):29–36. https://doi.org/10.1016/J.JACI.2020.11.013
doi: 10.1016/J.JACI.2020.11.013
pubmed: 33227318
Fokkens WJ, Lund VJ, Hopkins C et al (2020) European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl S29):1–464. https://doi.org/10.4193/RHIN20.600
doi: 10.4193/RHIN20.600
pubmed: 32078669
Mullol J, Bachert C, Amin N et al (2022) Olfactory outcomes with Dupilumab in Chronic Rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 10(4):1086–1095e5. https://doi.org/10.1016/J.JAIP.2021.09.037
doi: 10.1016/J.JAIP.2021.09.037
pubmed: 34628065
Chung JH, Lee YJ, Kang TW et al (2015) Altered quality of Life and Psychological Health (SCL-90-R) in patients with chronic Rhinosinusitis with nasal polyps. Ann Otol Rhinol Laryngol 124(8):663–670. https://doi.org/10.1177/0003489415576181
doi: 10.1177/0003489415576181
pubmed: 25743178
Kohli P, Naik AN, Harruff EE, Nguyen SA, Schlosser RJ, Soler ZM (2017) The prevalence of olfactory dysfunction in chronic rhinosinusitis. Laryngoscope 127(2):309–320. https://doi.org/10.1002/LARY.26316
doi: 10.1002/LARY.26316
pubmed: 27873345
Fokkens WJ, Lund V, Bachert C et al (2019) EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 74(12):2312–2319. https://doi.org/10.1111/ALL.13875
doi: 10.1111/ALL.13875
pubmed: 31090937
Fokkens WJ, Viskens AS, Backer V et al (2023) EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with nasal polyps 2023. Rhinology 61(3):194–202. https://doi.org/10.4193/RHIN22.489
doi: 10.4193/RHIN22.489
pubmed: 36999780
Seegräber M, Srour J, Walter A, Knop M, Wollenberg A (2018) Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 11(5):467–474. https://doi.org/10.1080/17512433.2018.1449642
doi: 10.1080/17512433.2018.1449642
pubmed: 29557246
Bachert C, Mannent L, Naclerio RM et al (2016) Effect of Subcutaneous Dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a Randomized Clinical Trial. JAMA 315(5):469–479. https://doi.org/10.1001/JAMA.2015.19330
doi: 10.1001/JAMA.2015.19330
pubmed: 26836729
Bachert C, Han JK, Desrosiers M et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet (London England) 394(10209):1638–1650. https://doi.org/10.1016/S0140-6736(19)31881-1
doi: 10.1016/S0140-6736(19)31881-1
pubmed: 31543428
Peters AT, Han JK, Hellings P et al (2021) Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 9(6):2461–2471e5. https://doi.org/10.1016/J.JAIP.2021.01.031
doi: 10.1016/J.JAIP.2021.01.031
pubmed: 33548517
Cai S, Xu S, Lou H, Zhang L (2022) Comparison of different biologics for treating chronic Rhinosinusitis with nasal polyps: A Network Analysis. J Allergy Clin Immunol Pract 10(7):1876–1886e7. https://doi.org/10.1016/J.JAIP.2022.02.034
doi: 10.1016/J.JAIP.2022.02.034
pubmed: 35272073
van der Lans RJL, Fokkens WJ, Adriaensen GFJPM, Hoven DR, Drubbel JJ, Reitsma S (2022) Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy 77(2):670–674. https://doi.org/10.1111/ALL.15134
doi: 10.1111/ALL.15134
pubmed: 34626497
De Corso E, Pasquini E, Trimarchi M et al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL). Allergy Eur J Allergy Clin Immunol 78(10):2669–2683. https://doi.org/10.1111/ALL.15772
doi: 10.1111/ALL.15772
Nettis E, Brussino L, Patella V et al (2022) Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life. Clin Mol Allergy 20(1). https://doi.org/10.1186/S12948-022-00171-2
Riera CE, Tsaousidou E, Halloran J et al (2017) The Sense of Smell Impacts Metabolic Health and Obesity. Cell Metab 26(1):198–211e5. https://doi.org/10.1016/J.CMET.2017.06.015
doi: 10.1016/J.CMET.2017.06.015
pubmed: 28683287
Aschenbrenner K, Hummel C, Teszmer K et al (2008) The influence of olfactory loss on dietary behaviors. Laryngoscope 118(1):135–144. https://doi.org/10.1097/MLG.0B013E318155A4B9
doi: 10.1097/MLG.0B013E318155A4B9
pubmed: 17975508
Matiashova L, Hoogkamer AL, Timper K (2023) The role of the olfactory system in obesity and metabolism in humans: a systematic review and Meta-analysis. Metab 2024 14(1):16. https://doi.org/10.3390/METABO14010016
doi: 10.3390/METABO14010016
Nitro L, De Corso E, Borin MPC Role of body Mass Index as a predictor of Dupilumab efficacy in patients with severe CRSwNP. Acta Otorhinolaryngol Ital. Accepted feb 2024 under print
De Corso E, Bellocchi G, De Benedetto M et al (2022) Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital 42(1):1. https://doi.org/10.14639/0392-100X-N1614
doi: 10.14639/0392-100X-N1614
pubmed: 34297014
Berek K, Hegen H, Auer M et al (2023) Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis. Mult Scler. https://doi.org/10.1177/13524585231201093
doi: 10.1177/13524585231201093
pubmed: 37850472
pmcid: 10782652
Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T (2019) Updated Sniffin’ sticks normative data based on an extended sample of 9139 subjects. Eur Arch Oto-Rhino-Laryngology 276(3):719. https://doi.org/10.1007/S00405-018-5248-1
doi: 10.1007/S00405-018-5248-1
Chung KF, Wenzel SE, Brozek JL et al (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2):343–373. https://doi.org/10.1183/09031936.00202013
doi: 10.1183/09031936.00202013
pubmed: 24337046
Haloob N, Karamali K, Hopkins C (2023) The role of Biologics in the treatment of Chronic Rhinosinusitis. BioDrugs 37(4):477–487. https://doi.org/10.1007/S40259-023-00602-9
doi: 10.1007/S40259-023-00602-9
pubmed: 37318659
Förster-Ruhrmann U, Stergioudi D, Szczepek AJ et al (2023) A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics. World Allergy Organ J 16(2). https://doi.org/10.1016/J.WAOJOU.2023.100746
Cantone E, De Corso E, Ricciardiello F et al (2022) Olfaction recovery following Dupilumab is Independent of Nasal Polyp reduction in CRSwNP. J Pers Med 12(8). https://doi.org/10.3390/JPM12081215
Boesveldt S, de Graaf K (2017) The Differential Role of Smell and Taste For Eating Behavior. 46(3–4):307–319. https://doi.org/10.1177/0301006616685576
Zhang T, Spence C (2023) Orthonasal olfactory influences on consumer food behaviour. Appetite 190. https://doi.org/10.1016/J.APPET.2023.107023
Stafford LD, Whittle A (2015) Obese individuals have higher preference and sensitivity to odor of chocolate. Chem Senses 40(4):279–284. https://doi.org/10.1093/CHEMSE/BJV007
doi: 10.1093/CHEMSE/BJV007
pubmed: 25771359
Herman CP, Polivy J (2008) External cues in the control of food intake in humans: the sensory-normative distinction. Physiol Behav 94(5):722–728. https://doi.org/10.1016/J.PHYSBEH.2008.04.014
doi: 10.1016/J.PHYSBEH.2008.04.014
pubmed: 18499202
Johansson EK, Ivert LU, Bradley B, Lundqvist M, Bradley M (2020) Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. BMC Dermatol 20(1):1–7. https://doi.org/10.1186/S12895-020-00103-0/TABLES/2
doi: 10.1186/S12895-020-00103-0/TABLES/2
Ottaviano G, De Corso E, Cantone E et al (2023) Measuring Nasal Patency and the sense of Smell in CRSwNP patients treated with Dupilumab. J Pers Med 13(2). https://doi.org/10.3390/JPM13020234
Rice JB, White AG, Scarpati LM, Wan G, Nelson WW (2017) Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 39(11):2216–2229. https://doi.org/10.1016/J.CLINTHERA.2017.09.011
doi: 10.1016/J.CLINTHERA.2017.09.011
pubmed: 29055500